Suzana Kahn

Sr. Director, Biology | Palo Alto, California, United States

Professional Overview

Suzana Kahn is an accomplished Sr. Director of Biology with extensive experience in the pharmaceutical and biotechnology industries. She has a proven track record of driving innovation, leading cross-functional teams, and delivering impactful results in the areas of immuno-oncology, target discovery, and drug development.

Experience Summary

Current Role

As the Sr. Director of Biology at Pheast Therapeutics, Suzana oversees a team of scientists and plays a key role in advancing the company's pipeline of novel therapeutics. She is responsible for directing research programs, designing and implementing effective experimental strategies, and collaborating with cross-functional partners to accelerate drug candidate selection and development.

Career Progression

Prior to her current role, Suzana served as the Director of Biology at Pheast Therapeutics, where she led a team of researchers and contributed to the company's success in progressing multiple drug candidates through preclinical and early clinical stages. Before joining Pheast, she held senior scientist positions at Genentech and Bristol Myers Squibb, where she spearheaded immuno-oncology target discovery initiatives and made significant contributions to the advancement of several investigational therapies.

Suzana's career trajectory includes a Pew Postdoctoral Fellowship at Stanford University, where she conducted groundbreaking research in the lab of renowned scientist, Dr. Irving Weissman. She also has experience as a Scientist at the National Institute for Traumatology and Orthopedics in Brazil and as a Postdoctoral Scholar at the Federal University of Rio de Janeiro.

Academic Background

Suzana holds a Ph.D. in Molecular and Cellular Biology from the Université Paris-Sorbonne, where she specialized in immunology and immune regulation. Her doctoral research focused on the development of novel therapeutic approaches for autoimmune disorders.

Areas of Expertise

• Immuno-oncology target discovery and validation

• Preclinical drug development and candidate selection

• Innovative experimental design and data analysis

• Cross-functional team leadership and collaboration

• Strategic decision-making and project management

Professional Impact

Suzana's work has had a significant impact on the pharmaceutical and biotechnology industries. She has contributed to the advancement of several investigational therapies, including the successful completion of multiple preclinical studies and the initiation of early-stage clinical trials. Her expertise in immuno-oncology target discovery has led to the identification of novel targets with the potential to transform patient outcomes.

Conclusion

With her exceptional scientific acumen, strategic leadership, and proven track record of success, Suzana Kahn is poised to continue making valuable contributions to the field of drug development and the advancement of innovative therapies that address unmet medical needs.